MedPath

DEXAMETHASONE AS ADJUVANT FOR PERIPHERAL NERVE BLOCKADE: A RANDOMIZED, TRIPLE-BLINDED AND CROSSOVER STUDY IN VOLUNTEERS- dexamethasone for peripheral nerve blocks

Phase 2
Conditions
Healthy volunteers
Registration Number
DRKS00014604
Lead Sponsor
Medizinische Universität Wien
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Male
Target Recruitment
24
Inclusion Criteria

• Healthy males
• Healthy, according to the medical history, ECG, vital signs, laboratory results and physical examination as determined by the Investigator/ Sub-Investigator
• Signed written informed consent prior to inclusion in the study
• 18-55 years old inclusive
• Clearly detectable ulnar nerve at the non-dominant arm in ultrasound evaluation, according to the main investigators opinion
• BMI: 18 to 35 kg/m2
• Ability to understand the full nature and purpose of the study, including possible risks and side effects
• Ability to co- operate with the investigator and to comply with the requirements of the entire study
• Availability to volunteer for the entire study duration and willing to adhere to all protocol requirements

Exclusion Criteria

• Any clinically relevant abnormalities at ECG (12 leads)
• Any clinically relevant abnormal physical findings
• Any clinically relevant abnormal laboratory values indicative of physical illness
• Ascertained or presumptive hypersensitivity to the active principle and/ or formulations ingredients of the study drug
• History of anaphylaxis to drugs or allergic reactions in general, which the investigator considers may affect the outcome of the study
• If the ulnar nerve is not clearly visible in ultrasound
• Relevant history of malignancy, of renal, hepatic, cardiovascular, respiratory, gastrointestinal, musculoskeletal, skin (particularly at the site of drug application), haematological, endocrine or neurological diseases that may interfere with the aim of the study
• Any psychiatric illnesses
• Using other medications during 1 week before the start of IMP application including OTC
• Participation in another clinical study investigating another IMP within 1 month prior to screening
• Blood donations during 4 weeks prior to this study
• History of drug or alcohol abuse (>2 drinks/ day, defined according to USDA Dietary Guidelines 2015)
• Other objections to study participation in the opinion of the investigator

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath